Laryngoscopy and intubation cause hypertension, tachycardia and arrhythmias [1, 2] and attenuation of these changes is important in patients with coronary artery disease. Various attempts have been made to block this stress response, but most are only partially successful [3] [4] [5] [6] [7] .
Laryngoscopy and intubation cause hypertension, tachycardia and arrhythmias [1, 2] and attenuation of these changes is important in patients with coronary artery disease. Various attempts have been made to block this stress response, but most are only partially successful [3] [4] [5] [6] [7] .
Calcium blocking drugs produce dilatation of both peripheral and coronary arteries [8] . The present study was designed to assess the efficacy of the calcium blocking agent nifedipine in attenuating the hypertensive response to laryngoscopy and intubation.
PATIENTS AND METHODS
The study was undertaken in 40 healthy normotensive patients (ASA grade I) in the age range 30-40 yr undergoing elective surgery. Informed consent was obtained in all instances. No patient was receiving sedative, anti-hypertensive or other medication likely to interfere with this study. The patients were allocated randomly to a control (n = 20) or nifedipine (n = 20) group.
Premedication consisted of diazepam 10 mg by mouth on the evening before surgery and also 2 h before induction of anaesthesia. In addition, all patients received morphine 0.2 mg kg" 1 and promethazine 0.5 mg kg" 1 1 h before induction. In the anaesthetic room, heart rate and arterial pressures (systolic, diastolic and mean) were recorded using an automatic monitor (Nippon Colin Co., Japan) and an i.v. infusion was commenced with 5 % dextrose.
Patients were given sublingually, by the second author, either a nifedipine gelatine capsule (10 mg) or a placebo capsule of similar appearance (random allocation). ECG monitoring was instituted and 10 min after administration of the sublingual capsule, anaesthesia was induced with thiopentone 5.5 mg kg" 1 over a period of 45 s, followed by suxamethonium 1.5 mg kg" 1 . Laryngoscopy was attempted 60 s after suxamethonium and tracheal intubation was completed within 30 s in all patients. All intubations were performed by the first author, who was unawareof the nature of the sublingual capsule. Serial heart rate and arterial pressure measurements were obtained before and after induction, after administration of suxamethonium, immediately and 1, 2 and 3 min following laryngoscopy and intubation.
SUMMARY
Anaesthesia was maintained with 70% nitrous oxide in oxygen; ventilation was spontaneous, assisted or controlled, as required. After tracheal intubation, ventilation was controlled using the same gas mixture delivered by a Servo ventilator (Siemens Elema 900 B) at a rate of 12 b.p.m. and BRITISH JOURNAL OF ANAESTHESIA VE of approximately 110 ml kg" 1 . Following recovery from suxamethonium, pancuronium 4 mg was given i.v.
Student's t test for paired observations was used for analysis within the groups, and that for unpaired observations for analysis between groups. P < 0.05 was considered statistically significant.
RESULTS
There were no significant differences between the two groups in respect of mean age or weight (34.6 + 3.9 yr, 64.9 + 4.2 kg in control patients compared with 36.3 + 3.6 yr, 65.9 + 5.4 kg in nifedipine treated patients (mean+SD)). There was no statistically significant difference between the two groups in respect of mean heart rate (HR), systolic arterial pressure (SAP) and mean arterial pressure (MAP) at 0 and 10 min.
SAP and MAP decreased following induction in both groups, but there was no significant difference between the two groups. In response to laryngoscopy and intubation, SAP and MAP increased significantly in control patients (P < 0.001), while the increase was significantly less in the nifedipine treated group (P < 0.01). The increase in SAP and MAP in group B patients after intubation was 0.9 mm Hg and 3.9 mm Hg, respectively, compared with 20.2 mm Hg and 22.8 mm Hg in control patients (table I) .
There was an increase in heart rate after induction, laryngoscopy and intubation in both groups (P < 0.001), but no significant difference existed between groups at any stage.
The rate-pressure product (RPP) was significantly higher in control compared with nifedipine treated patients after laryngoscopy and intubation and at 1, 2 and 3 min following intubation (P < 0.001) (table I).
The duration of surgery in control (85.5 + 12.3 min) and nifedipine treated patients (86 + 10.5 min), and requirements for pancuronium (5.7 ±0.6 mg and 5.7 + 0.5 mg, respectively) were comparable.
DISCUSSION
Nifedipine is an antagonist of calcium influx through the slow channel of the cell membrane and has been shown to be an effective treatment for stable, variant and unstable angina and mild to severe hypertension [9] [10] [11] . Our study has shown that sublingual nifedipine attenuated the increase in SAP and MAP produced by laryngoscopy and tracheal intubation. Although tachycardia was not obviated, the increase in RPP, an index of myocardial oxygen consumption, was significantly attenuated. The administration of sublingual nifedipine did not produce undue hypotension.
Nifedipine is absorbed well by the oral or sublingual route. After single sublingual administration of nifedipine 10 mg, measurable plasma concentrations were present within 6 min in 50 % of volunteers [12] . The onset of an antihypertensive action is obvious within 5-8 min after sublingual administration with peak effects occurring at 20-30 min [13] . The elimination half-life following oral administration varies between 2 and 3.4 h [14] .
Sublingual nifedipine has been found to be a safe and effective drug for the acute lowering of increased arterial pressure resulting from surgery [15] . However, calcium antagonists may cause an exaggerated hypotensive response in the presence of volatile anaesthetic agents by either further reducing systemic vascular resistance or reducing myocardial contractility, or a combination of these effects.
In conclusion, we have shown that sublingual nifedipine attenuates the hypertensive response to laryngoscopy and intubation. However, the role of this technique for suppressing pressor responses in the hypertensive patient at the time of tracheal intubation requires further study.
